TQC2731
Phase 3Small molecule
TQC2731 is one of 84 small molecule programs targeting Sinusitis. It is currently in Phase 3.
2
Indications
6
Total Trials
3
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
120 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Lunsekimig
SanofiPhase 3
Tozorakimab
AstraZenecaPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Astegolimab
RochePhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
TQC2731
SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
Titrated Oxygen
RRigshospitalet, Denmark
Phase 3
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma2 trials
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injections in Patients With Poorly Controlled Severe Asthma
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT06829784·660 enrolled
Chronic Obstructive Pulmonary Disease1 trial
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Active, not recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT06707883·258 enrolled
Sinusitis1 trial
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07107256·246 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQC2731. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details